company background image
2M7C logo

China Medical System Holdings DB:2M7C Stock Report

Last Price

€0.93

Market Cap

€2.3b

7D

5.1%

1Y

-43.3%

Updated

02 Dec, 2024

Data

Company Financials +

China Medical System Holdings Limited

DB:2M7C Stock Report

Market Cap: €2.3b

China Medical System Holdings Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for China Medical System Holdings
Historical stock prices
Current Share PriceHK$0.93
52 Week HighHK$1.69
52 Week LowHK$0.71
Beta0.93
11 Month Change4.49%
3 Month Change12.05%
1 Year Change-43.29%
33 Year Change-31.11%
5 Year Change-26.77%
Change since IPO227.77%

Recent News & Updates

Recent updates

Shareholder Returns

2M7CDE PharmaceuticalsDE Market
7D5.1%-1.5%1.5%
1Y-43.3%-19.6%8.8%

Return vs Industry: 2M7C underperformed the German Pharmaceuticals industry which returned -19.6% over the past year.

Return vs Market: 2M7C underperformed the German Market which returned 7.8% over the past year.

Price Volatility

Is 2M7C's price volatile compared to industry and market?
2M7C volatility
2M7C Average Weekly Movement6.9%
Pharmaceuticals Industry Average Movement6.9%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.9%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 2M7C's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 2M7C's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
19955,781Kong Lamweb.cms.net.cn/zh/home/

China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. Its products include VALTOCO, a diazepam nasal spray to treat seizure clusters; Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu to treat acute heart failure; Deanxit for mild-to-moderate depression, anxiety, and psychosomatic affections; METOJECT, a methotrexate injection for recalcitrant disabling psoriasis; and Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis. The company also offers Salofalk for treating Ulcerative Colitis and Crohn’s disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; ILUMETRI, a tildrakizumab injection to treat moderate-tosevere plaque psoriasis; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar.

China Medical System Holdings Limited Fundamentals Summary

How do China Medical System Holdings's earnings and revenue compare to its market cap?
2M7C fundamental statistics
Market cap€2.30b
Earnings (TTM)€182.02m
Revenue (TTM)€918.33m

12.6x

P/E Ratio

2.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2M7C income statement (TTM)
RevenueCN¥7.01b
Cost of RevenueCN¥1.85b
Gross ProfitCN¥5.17b
Other ExpensesCN¥3.78b
EarningsCN¥1.39b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.58
Gross Margin73.66%
Net Profit Margin19.82%
Debt/Equity Ratio6.9%

How did 2M7C perform over the long term?

See historical performance and comparison

Dividends

5.4%

Current Dividend Yield

40%

Payout Ratio